The effects of the IRA on Scienture LLC’s business and the healthcare industry in general is not yet known.
All entries for: Endocrinology
March 27, 2026
Entera Bio Ltd
Neutral Outlook
Jerusalem, Israel
1-50 employees
Further, on August 16, 2022, Congress enacted the Inflation Reduction Act allowing CMS to negotiate directly with drug manufacturers to lower the price of some of the costliest drugs under the Medicare program, as well as requiring drug manufacturers to provide Medicare with a rebate if the price of drugs increases faster than the rate of inflation.
Disease Area: Endocrinology, Metabolic Diseases
Drug Type: Biologic
March 18, 2026
ProKidney Corp.
Neutral Outlook
Winston-Salem, NC
51-200 employees
However, the IRA’s impact on the pharmaceutical industry in the United States remains uncertain, in part because multiple large pharmaceutical companies and other stakeholders (e.g., the U.S. Chamber of Commerce) have initiated federal lawsuits against CMS arguing the program is unconstitutional for a variety of reasons, among other complaints. Those lawsuits are currently ongoing.
Disease Area: Endocrinology
Drug Type: Biologic
March 13, 2026
Nektar Therapeutics
Neutral Outlook
San Francisco, CA
51-200 employees
Although the effects of the IRA on our business and the healthcare industry in general are not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
Disease Area: Dermatology, Endocrinology, Immune Diseases, Neurological Diseases, Oncology
Drug Type: Biologic
March 9, 2026
Macrogenics Inc
Neutral Outlook
Rockville, MD
201-500 employees
For example, on August 16, 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law, which among other things, (i) extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025, (ii) authorizes HHS to negotiate the price of certain high-expenditure, single-source drugs covered under Medicare that have been on the market for at least 7 years, and (iii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation.
Disease Area: Endocrinology, Hematology, Oncology
Drug Type: Biologic